Stock OCS OCULIS HOLDING AG
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Oculis Holding AG

Equities

OCS

CH1242303498

End-of-day quote Nasdaq
Other stock markets
 06:00:00 2024-05-27 pm EDT 		5-day change 1st Jan Change
11.9 USD +0.42% Intraday chart for Oculis Holding AG 0.00% +5.97%
10:00am Oculis Holding AG Announces Board and Committee Appointments CI
May. 08 Oculis Holding AG Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • Based on current prices, the company has particularly high valuation levels.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the last few months, analysts have been revising downwards their earnings forecast.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
OCULIS HOLDING AG Stock Oculis Holding AG
+5.97% 498M -
MODERNA, INC. Stock Moderna, Inc.
+47.08% 56.69B
B-
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-3.28% 41B
B
LONZA GROUP AG Stock Lonza Group AG
+38.90% 38.11B
A
CELLTRION, INC. Stock Celltrion, Inc.
-11.22% 26.89B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+10.99% 25.59B
B-
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.57% 18.59B
B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-0.52% 12.39B
B+
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+25.29% 11.99B
C+
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+22.31% 11.88B
B+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
-
  1. Stock Market
  2. Equities
  3. OCS Stock
  4. Ratings Oculis Holding AG